Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Camlipixant · BLU-5937, GSK5464714

Small molecule · developed by GSK

Phase 3 Most advanced trial
GSK Developer
4 Registered trials

What is Camlipixant?

Camlipixant (BLU-5937, GSK5464714) is an orally administered agent studied in refractory chronic cough and in healthy subjects.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BLU-5937, GSK5464714, [14C]-BLU-5937
Drug type
Small molecule
Therapy area
Respiratory
Developer
GSK (GSK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
TB7D2H7MZZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05600777 Phase 3 Cough Active not recruiting GSK
NCT06497517 Phase 1 Cough Completed GSK
NCT06222892 Phase 1 Cough Completed GSK
NCT05244759 Phase 1 Healthy Completed GSK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CoughRefractory Chronic CoughHealthy

More from GSK

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.

Follow GSK, the company behind Camlipixant

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.